Courtois et al., 2023 - Google Patents
IL-7 receptor expression is frequent in T-cell acute lymphoblastic leukemia and predicts sensitivity to JAK inhibitionCourtois et al., 2023
View HTML- Document ID
- 9059246675420686722
- Author
- Courtois L
- Cabannes-Hamy A
- Kim R
- Delecourt M
- Pinton A
- Charbonnier G
- Feroul M
- Smith C
- Tueur G
- Pivert C
- Balducci E
- Simonin M
- Angel L
- Spicuglia S
- Boissel N
- Andrieu G
- Asnafi V
- Rousselot P
- Lhermitte L
- Publication year
- Publication venue
- Blood, The Journal of the American Society of Hematology
External Links
Snippet
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy with a dismal prognosis related to refractory/relapsing diseases, raising the need for new targeted therapies. Activating mutations of interleukin-7–receptor pathway genes (IL-7Rp) …
- 208000029052 T-cell acute lymphoblastic leukemia 0 title abstract description 235
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
- C12Q1/6886—Hybridisation probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Courtois et al. | IL-7 receptor expression is frequent in T-cell acute lymphoblastic leukemia and predicts sensitivity to JAK inhibition | |
| Haradhvala et al. | Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma | |
| Dyck et al. | Suppressive effects of the obese tumor microenvironment on CD8 T cell infiltration and effector function | |
| Schmoellerl et al. | CDK6 is an essential direct target of NUP98 fusion proteins in acute myeloid leukemia | |
| Chakraborty et al. | Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis | |
| Carvajal et al. | KIT as a therapeutic target in metastatic melanoma | |
| Thol et al. | Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes | |
| Maude et al. | Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia | |
| Chou et al. | Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation | |
| Heuser et al. | High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics | |
| Harvey et al. | Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia | |
| Thol et al. | Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes | |
| Lim et al. | Integration of Hedgehog and mutant FLT3 signaling in myeloid leukemia | |
| Xie et al. | Targeting ESE3/EHF with nifurtimox inhibits CXCR2+ neutrophil infiltration and overcomes pancreatic cancer resistance to chemotherapy and immunotherapy | |
| Schnell et al. | Therapeutic targeting of HES1 transcriptional programs in T-ALL | |
| Rundberg Nilsson et al. | IRF1 regulates self-renewal and stress responsiveness to support hematopoietic stem cell maintenance | |
| Wang et al. | Biomarkers for predicting the efficacy of immune checkpoint inhibitors | |
| Saygin et al. | Acute lymphoblastic leukemia with myeloid mutations is a high-risk disease associated with clonal hematopoiesis | |
| Shieh et al. | Defective K-Ras oncoproteins overcome impaired effector activation to initiate leukemia in vivo | |
| Li et al. | Impact of T-cell immunity on chemotherapy response in childhood acute lymphoblastic leukemia | |
| Chan et al. | Single-cell landscape of idiopathic multicentric Castleman disease in identical twins | |
| Yang et al. | Longitudinal circulating tumor DNA profiling in metastatic colorectal cancer during anti-EGFR therapy | |
| Schreck et al. | Response rate and molecular correlates to encorafenib and binimetinib in BRAF-V600E mutant high-grade glioma | |
| Kemps et al. | Recurrent CLTC:: SYK fusions and CSF1R mutations in juvenile xanthogranuloma of soft tissue | |
| Savardekar et al. | Single-cell RNA-seq analysis of patient myeloid-derived suppressor cells and the response to inhibition of bruton's tyrosine kinase |